Merck & Co., Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Merck & Co., Inc. (MRK) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.90% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-02-24
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-03-31 was 2.70%, a 35.00% increase year-over-year.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-03-31 was 2.00%, a 53.85% increase year-over-year.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2016-03-31 was 1.30%, a 23.53% decline year-over-year.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-03-31 was 1.70%, a 19.05% decline year-over-year.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.90%, a 17.02% decline from fiscal 2024.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.70%, a 38.24% increase from fiscal 2023.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.40%, a 13.33% increase from fiscal 2022.
- Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.00%, a 200.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 3.90% 10-K · filed 2026-02-24 | |||
| 2024-12-31 | 4.70% 10-K · filed 2026-02-24 | |||
| 2023-12-31 | 3.40% 10-K · filed 2026-02-24 | |||
| 2022-12-31 | 3.00% 10-K · filed 2025-02-25 | |||
| 2021-12-31 | 1.00% 10-K · filed 2024-02-26 | |||
| 2020-12-31 | 0.40% 10-K · filed 2023-02-24 | |||
| 2020-09-30 | 0.40% 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | 0.40% 10-Q · filed 2020-08-05 | |||
| 2019-12-31 | 2.40% 10-K · filed 2022-02-25 | |||
| 2019-09-30 | 2.40% 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | 2.40% 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | 2.90% 10-K · filed 2021-02-25 | |||
| 2018-09-30 | 2.80% 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | 2.80% 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | 2.70% 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | 2.00% 10-K · filed 2020-02-26 | |||
| 2017-09-30 | 2.00% 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | 2.00% 10-Q · filed 2018-08-07 | |||
| 2017-03-31 | 2.00% 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | 1.40% 10-K · filed 2019-02-27 | |||
| 2016-09-30 | 1.40% 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | 1.40% 10-Q · filed 2017-08-08 | |||
| 2016-03-31 | 1.30% 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | 1.70% 10-K · filed 2018-02-27 | |||
| 2015-09-30 | 1.70% 10-Q · filed 2016-11-07 | |||
| 2015-06-30 | 1.70% 10-Q · filed 2016-08-08 | |||
| 2015-03-31 | 1.70% 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | 2.00% 10-K · filed 2017-02-28 | |||
| 2014-09-30 | 2.00% 10-Q · filed 2015-11-05 | |||
| 2014-06-30 | 2.00% 10-Q · filed 2015-08-06 | |||
| 2014-03-31 | 2.10% 10-Q · filed 2015-05-07 | |||
| 2013-12-31 | 1.20% 10-K · filed 2016-02-26 | |||
| 2013-09-30 | 1.20% 10-Q · filed 2014-11-10 | |||
| 2013-06-30 | 1.20% 10-Q · filed 2014-08-07 | |||
| 2012-12-31 | 1.30% 10-K · filed 2015-02-27 | |||
| 2012-09-30 | 1.30% 10-Q · filed 2013-11-07 | |||
| 2012-06-30 | 1.30% 10-Q · filed 2013-08-07 | |||
| 2012-03-31 | 1.40% 10-Q · filed 2013-05-09 | |||
| 2011-12-31 | 2.50% 10-K · filed 2014-02-27 | |||
| 2011-09-30 | 2.60% 10-Q · filed 2012-11-09 | |||
| 2011-06-30 | 2.60% 10-Q · filed 2012-08-07 | |||
| 2011-03-31 | 3.10% 10-Q · filed 2012-05-08 | |||
| 2010-12-31 | 2.80% 10-K · filed 2013-02-28 | |||
| 2010-09-30 | 2.80% 10-Q · filed 2011-11-08 | |||
| 2010-06-30 | 2.80% 10-Q · filed 2011-08-08 | |||
| 2010-03-31 | 2.70% 10-Q · filed 2011-05-09 | |||
| 2009-12-31 | 2.20% 10-K · filed 2012-02-28 | |||
| 2009-09-30 | 2.20% 10-Q · filed 2010-11-08 | |||
| 2009-06-30 | 2.10% 10-Q · filed 2010-08-06 | |||
| 2008-12-31 | 2.70% 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |